<code id='4626E6BFCC'></code><style id='4626E6BFCC'></style>
    • <acronym id='4626E6BFCC'></acronym>
      <center id='4626E6BFCC'><center id='4626E6BFCC'><tfoot id='4626E6BFCC'></tfoot></center><abbr id='4626E6BFCC'><dir id='4626E6BFCC'><tfoot id='4626E6BFCC'></tfoot><noframes id='4626E6BFCC'>

    • <optgroup id='4626E6BFCC'><strike id='4626E6BFCC'><sup id='4626E6BFCC'></sup></strike><code id='4626E6BFCC'></code></optgroup>
        1. <b id='4626E6BFCC'><label id='4626E6BFCC'><select id='4626E6BFCC'><dt id='4626E6BFCC'><span id='4626E6BFCC'></span></dt></select></label></b><u id='4626E6BFCC'></u>
          <i id='4626E6BFCC'><strike id='4626E6BFCC'><tt id='4626E6BFCC'><pre id='4626E6BFCC'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:656
          Boxes of Wegovy — pharma coverage from STAT
          Carsten Snejbjerg/Bloomberg

          LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs. 

          Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

          advertisement

          Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more
          Grail's uphill battle for Medicare to cover its cancer screening test
          Grail's uphill battle for Medicare to cover its cancer screening test

          GrailWASHINGTON—GrailisaggressivelylobbyingtogetMedicaretopayforitscancer-screeningtestGalleri—butex

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Sickle cell gene therapy cures need to be accessible in Africa

          Redbloodcellsfromapersonwithsicklecelldisease.JonathanArmstrong/WellcomeThetreatmentofsicklecelldise